Advertisement

Ketamine: The Glutamatergic Antidepressant and Its Efficacy

  • Derek K. Tracy
  • Caroline Caddy
  • Sukhwinder S. Shergill
Chapter

Abstract

Ketamine, an uncompetitive glutamatergic NMDA antagonist, was first synthesised as an anaesthetic agent, though its unwanted induction of post-operative ‘dissociative’ states led to its gradual withdrawal from mainstream use. It has remained a common drug of abuse ever since, in the same class as the more powerful phencyclidine (‘PCP’ or ‘angel-dust’). However, as well as subjectively pleasurable perceptual changes and alterations to consciousness, data began to emerge of a positive effect upon depressed mood states. Of particular interest, such effects, where they occurred, were seen to develop far more rapidly than with ‘traditional’ antidepressants. Scientific trials of effectiveness have included work exploring ketamine as the sole medication, co-prescribing studies, and work looking at augmentation of ECT. Overall these early data are showing some interesting and exciting results, with general support for efficacy in all settings tested. However, significant challenges remain. Firstly, benefits derived tend to be temporary, with rapid relapse after several weeks, and there is a need to find a mechanism to sustain the drug effects. Secondly, most studies utilised intravenous administration, which carries an obvious clinical burden. Finally, the risks of dependency and ketamine-induced psychosis remain as yet uncertain. Nevertheless the societal burden of depression mandates further work on this compound, not least to better understand the mechanism of action of any therapeutic changes.

Keywords

Major Depressive Disorder Suicidal Ideation Major Depressive Disorder Antidepressant Effect Bipolar Depression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgement

The authors are grateful to David Baumeister and Luis Tojo for their assistance with the literature on illicit dissociative drugs more broadly.

References

  1. 1.
    Aan Het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67:139–45.CrossRefPubMedGoogle Scholar
  2. 2.
    Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. J ECT. 2012;28:157–61.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Abdallah CG, Salas R, Jackowski A, Baldwin P, Sato Jr., Mathew SJ. Hippocampal volume and the rapid antidepressant effect of ketamine. J Psychopharmacol. 2015;29:591–5.Google Scholar
  4. 4.
    Abe H, Rusak B, Robertson HA. NMDA and non-NMDA receptor antagonists inhibit photic induction of Fos protein in the hamster suprachiasmatic nucleus. Brain Res Bull. 1992;28:831–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Albayrak Y, Ugurlu GK, Ugurlu M, Caykoylu A. Beneficial effects of fluvoxamine for chorea in a patient with huntington’s disease: a case report. Prim Care Companion CNS Disord. 2012;14:PCC.12l01369.Google Scholar
  6. 6.
    Antony LJ, Paruchuri VN, Ramanan R. Antidepressant effect of ketamine in sub anaesthetic doses in male albino mice. J Clin Diagn Res. 2014;8:HC05–7.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91–5.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA, Brutsche NE, Ameli R, Furey ML, Zarate Jr CA. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014;58:161–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Baumeister D, Barnes G, Giaroli G, Tracy D. Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol. 2014;4:156–69.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Bellet MM, Vawter MP, Bunney BG, Bunney WE, Sassone-Corsi P. Ketamine influences CLOCK:BMAL1 function leading to altered circadian gene expression. PLoS One. 2011;6:e23982.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Best SR, Griffin B. Combination therapy utilizing ketamine and transcranial magnetic stimulation for treatment-resistant depression: a case report. Int J Neurosci. 2015;125:232–4.Google Scholar
  13. 13.
    Beurel E, Song L, Jope RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry. 2011;16:1068–70.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Brown KM, Tracy DK. Lithium: the pharmacodynamic actions of the amazing ion. Ther Adv Psychopharmacol. 2013;3:163–76.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Carlson PJ, Diazgranados N, Nugent AC, Ibrahim L, Luckenbaugh DA, Brutsche N, et al. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry. 2013;73:1213–21.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Carpenter RA, Falkenburg J, White TP, Tracy DK. Crisis teams: systematic review of their effectiveness in practice. Psychiatrist. 2013;37:232–7.CrossRefGoogle Scholar
  17. 17.
    Carpenter RA, Tracy DK. Home treatment teams: what should they do? A qualitative study of patient options. In preparation. 2014.Google Scholar
  18. 18.
    Chilukuri H, Reddy NP, Pathapati RM, Manu AN, Jollu S, Shaik AB. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J Psychol Med. 2014;36:71–6.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Chu PS, Ma WK, Wong SC, Chu RW, Cheng CH, Wong S, Tse JM, Lau FL, Yiu MK, Man CW. The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int. 2008;102:1616–22.CrossRefPubMedGoogle Scholar
  20. 20.
    Colwell CS, Menaker M. NMDA as well as non-NMDA receptor antagonists can prevent the phase-shifting effects of light on the circadian system of the golden hamster. J Biol Rhythms. 1992;7:125–36.CrossRefPubMedGoogle Scholar
  21. 21.
    Critchlow DG. A case of ketamine dependence with discontinuation symptoms. Addiction. 2006;101:1212–3.CrossRefPubMedGoogle Scholar
  22. 22.
    Davis LL, Frazier EC, Gaynes BN, Trivedi MH, Wisniewski SR, Fava M, Barkin J, Kashner TM, Shelton RC, Alpert JE, Rush AJ. Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort. J Clin Psychiatry. 2007;68:1931–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, Geddes JR, Mcshane R. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol. 2014;28:536–44.CrossRefPubMedGoogle Scholar
  24. 24.
    Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate Jr CA. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793–802.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Diazgranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, Machado-Vieira R, Zarate Jr CA. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71:1605–11.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Du J, Machado-Vieira R, Maeng S, Martinowich K, Manji HK, Zarate CA. Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action. Drug Discov Today. 2006;3:519–26.Google Scholar
  27. 27.
    Du J, Suzuki K, Wei Y, Wang Y, Blumenthal R, Chen Z, Falke C, Zarate JR CA, Manji HK. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology. 2007;32:793–802.Google Scholar
  28. 28.
    Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med. 2004;5:11–25.CrossRefPubMedGoogle Scholar
  29. 29.
    Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci. 2012;35:47–56.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Dunbar R. Human evolution. London: Pelican; 2014.Google Scholar
  31. 31.
    Duncan WC, Sarasso S, Ferrarelli F, Selter J, Riedner BA, Hejazi NS, Yuan P, Brutsche N, Manji HK, Tononi G, Zarate CA. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol. 2013;16:301–11.CrossRefPubMedGoogle Scholar
  32. 32.
    Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001;62:869–77.CrossRefPubMedGoogle Scholar
  33. 33.
    Erdil F, Begec Z, Kayhan GE, Yologlu S, Ersoy MO, Durmus M. Effects of sevoflurane or ketamine on the QTc interval during electroconvulsive therapy. J Anesth. 2015;29:180–5.Google Scholar
  34. 34.
    Ghasemi M, Kazemi MH, Yoosefi A, Ghasemi A, Paragomi P, Amini H, Afzali MH. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res. 2014;215:355–61.CrossRefPubMedGoogle Scholar
  35. 35.
    Green SM, Clark R, Hostetler MA, Cohen M, Carlson D, Rothrock SG. Inadvertent ketamine overdose in children: clinical manifestations and outcome. Ann Emerg Med. 1999;34:492–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Guo M, Lu Y, Garza JC, Li Y, Chua SC, Zhang W, Lu B, Lu XY. Forebrain glutamatergic neurons mediate leptin action on depression-like behaviors and synaptic depression. Transl Psychiatry. 2012;2:e83.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Hamilton JP, Furman DJ, Chang C, Thomason ME, Dennis E, Gotlib IH. Default-mode and task-positive network activity in major depressive disorder: implications for adaptive and maladaptive rumination. Biol Psychiatry. 2011;70:327–33.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Hayashi T, Su TP. An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand. Expert Opin Ther Targets. 2008;12:45–58.CrossRefPubMedGoogle Scholar
  39. 39.
    Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP. Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin Ther Targets. 2011;15:557–77.CrossRefPubMedGoogle Scholar
  40. 40.
    Herling PL. Excitatory amino acids: clinical results with antagonists. California: Academic Press; 1997.Google Scholar
  41. 41.
    Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2010;33:67–75.CrossRefPubMedGoogle Scholar
  42. 42.
    Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, Moaddel R, Wainer I, Luckenbaugh DA, Manji HK, Zarate Jr CA. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012;37:1526–33.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Irwin SA, Iglewicz A, Nelesen RA, Lo JY, Carr CH, Romero SD, Lloyd LS. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med. 2013;16:958–65.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Ishima T, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: the role of sigma-1 and IP3 receptors. PLoS One. 2012;7:e37989.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Jarventausta K, Chrapek W, Kampman O, Tuohimaa K, Bjorkqvist M, Hakkinen H, Yli-Hankala A, Leinonen E. Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. J ECT. 2013;29:158–61.CrossRefPubMedGoogle Scholar
  46. 46.
    Jernigan CS, Goswami DB, Austin MC, Iyo AH, Chandran A, Stockmeier CA, Karolewicz B. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1774–9.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Kapur S, Phillips AG, Insel TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry. 2012;17:1174–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Ke X, Ding Y, Xu K, He H, Zhang M, Wang D, Deng X, Zhang X, Zhou C, Liu Y, Ning Y, Fan N. Serum brain-derived neurotrophic factor and nerve growth factor decreased in chronic ketamine abusers. Drug Alcohol Depend. 2014;142:290–4.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Kelly BC, Wells BE, Leclair A, Tracy D, Parsons JT, Golub SA. Prevalence and correlates of prescription drug misuse among socially active young adults. Int J Drug Policy. 2013;24:297–303.CrossRefPubMedGoogle Scholar
  50. 50.
    Kinsler R, Duman R. Acute ketamine administration increases VEGF expression in the hippocampus: potential role in the rapid antidepressant effects of ketamine. Washington, DC: Society for Neuroscience; 2008.Google Scholar
  51. 51.
    Kranaster L, Kammerer-Ciernioch J, Hoyer C, Sartorius A. Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study. Eur Arch Psychiatry Clin Neurosci. 2011;261:575–82.CrossRefPubMedGoogle Scholar
  52. 52.
    Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers JR MB, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199–214.Google Scholar
  53. 53.
    Kudoh A, Takahira Y, Katagai H, Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg. 2002;95:114–8, table of contents.CrossRefPubMedGoogle Scholar
  54. 54.
    Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, Feder A, Iosifescu DV, Charney DS, Murrough JW. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76:970–6.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Lara DR, Bisol LW, Munari LR. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol. 2013;16:2111–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14:1127–31.CrossRefPubMedGoogle Scholar
  57. 57.
    Larson MK, Walker EF, Compton MT. Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Rev Neurother. 2010;10:1347–59.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Li B, Wang X, Yao S, Hu D, Friston K. Task-dependent modulation of effective connectivity within the default mode network. Front Psychol. 2012;3:206.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959–64.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Liu J, Garza JC, Bronner J, Kim CS, Zhang W, Lu XY. Acute administration of leptin produces anxiolytic-like effects: a comparison with fluoxetine. Psychopharmacology (Berl). 2010;207:535–45.CrossRefGoogle Scholar
  61. 61.
    Loo CK, Katalinic N, Garfield JB, Sainsbury K, Hadzi-Pavlovic D, Mac-Pherson R. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. J Affect Disord. 2012;142:233–40.CrossRefPubMedGoogle Scholar
  62. 62.
    Lu XY, Kim CS, Frazer A, Zhang W. Leptin: a potential novel antidepressant. Proc Natl Acad Sci U S A. 2006;103:1593–8.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry. 1959;81:363–9.CrossRefPubMedGoogle Scholar
  64. 64.
    Lundin NB, Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Brutsche NE, Machado-Vieira R, Zarate JR CA. Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine. Pharmacopsychiatry. 2014;47:141–4.Google Scholar
  65. 65.
    Luppino FS, DE Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67:220–9.CrossRefPubMedGoogle Scholar
  66. 66.
    Ma XC, Dang YH, Jia M, Ma R, Wang F, Wu J, Gao CG, Hashimoto K. Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One. 2013;8:e56053.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Machado-Vieira R, Salvadore G, Diazgranados N, Zarate Jr CA. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther. 2009;123:143–50.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Macpherson RD, Loo CK. Cognitive impairment following electroconvulsive therapy – does the choice of anesthetic agent make a difference? J ECT. 2008;24:52–6.CrossRefPubMedGoogle Scholar
  69. 69.
    Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 1997;17:141–50.CrossRefPubMedGoogle Scholar
  70. 70.
    Mathew SJ, Murrough JW, Aan Het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13:71–82.CrossRefPubMedGoogle Scholar
  71. 71.
    Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl). 2006;188:408–24.CrossRefGoogle Scholar
  72. 72.
    Morgan CJ, Rees H, Curran HV. Attentional bias to incentive stimuli in frequent ketamine users. Psychol Med. 2008;38:1331–40.CrossRefPubMedGoogle Scholar
  73. 73.
    Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008;95:219–29.CrossRefPubMedGoogle Scholar
  74. 74.
    Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170:1134–42.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, Aan Het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74:250–6.CrossRefPubMedGoogle Scholar
  76. 76.
    Niciu MJ, Luckenbaugh DA, Ionescu DF, Guevara S, Machado-Vieira R, Richards EM, Brutsche NE, Nolan NM, Zarate Jr CA. Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry. 2014;75:e417–23.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One. 2008;3:e2558.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Okamoto N, Nakai T, Sakamoto K, Nagafusa Y, Higuchi T, Nishikawa T. Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. J ECT. 2010;26:223–7.CrossRefPubMedGoogle Scholar
  79. 79.
    Pal A, Fontanilla D, Gopalakrishnan A, Chae YK, Markley JL, Ruoho AE. The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements. Eur J Pharmacol. 2012;682:12–20.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Penn E, Tracy DK. The drugs don’t work? Antidepressants and the current and future pharmacological management of depression. Ther Adv Psychopharmacol. 2012;2:179–88.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Permoda-Osip A, Skibinska M, Bartkowska-Sniatkowska A, Kliwicki S, Chlopocka-Wozniak M, Rybakowski JK. Factors connected with efficacy of single ketamine infusion in bipolar depression. Psychiatr Pol. 2014;48:35–47.CrossRefPubMedGoogle Scholar
  82. 82.
    Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate Jr CA. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry. 2009;65:181–4.CrossRefPubMedGoogle Scholar
  83. 83.
    Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. 2012;13:22–37.Google Scholar
  84. 84.
    Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, Soleimani L, Charney DS, Foulkes AL, Mathew SJ. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014;31:335–43.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66:522–6.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Raichle ME, Macleod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98:676–82.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Rasmussen KG, Kung S, Lapid MI, Oesterle TS, Geske JR, Nuttall GA, Oliver WC, Abenstein JP. A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy. Psychiatry Res. 2014;215:362–5.CrossRefPubMedGoogle Scholar
  88. 88.
    Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, Ritter MJ, Schak KM, Sola CL, Hanson AJ, Frye MA. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 2013;27:444–50.CrossRefPubMedGoogle Scholar
  89. 89.
    Richardson E, Tracy DK. The borderline of bipolar: opinions of patients and lessons for clinicians on the diagnostic conflict. Psychiatr Bull. 2014;38:1–6.CrossRefGoogle Scholar
  90. 90.
    Rybakowski JK, Permoda-Osip A, Skibinska M, Adamski R, Bartkowska-Sniatkowska A. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum Psychopharmacol. 2013;28:87–90.CrossRefPubMedGoogle Scholar
  91. 91.
    Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate Jr CA, Manji HK. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry. 2009;65:289–95.CrossRefPubMedGoogle Scholar
  92. 92.
    Salvadore G, Cornwell BR, Sambataro F, Latov D, Colon-Rosario V, Carver F, Holroyd T, Diazgranados N, Machado-Vieira R, Grillon C, Drevets WC, Zarate Jr CA. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology. 2010;35:1415–22.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Salvadore G, Van Der Veen JW, Zhang Y, Marenco S, Machado-Vieira R, Baumann J, Ibrahim LA, Luckenbaugh DA, Shen J, Drevets WC, Zarate Jr CA. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol. 2012;15:1063–72.CrossRefPubMedGoogle Scholar
  94. 94.
    Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62:63–77.CrossRefPubMedGoogle Scholar
  95. 95.
    Scheidegger M, Walter M, Lehmann M, Metzger C, Grimm S, Boeker H, Boesiger P, Henning A, Seifritz E. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS One. 2012;7:e44799.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Schifano F, Corkery J, Oyefeso A, Tonia T, Ghodse AH. Trapped in the “K-hole”: overview of deaths associated with ketamine misuse in the UK (1993–2006). J Clin Psychopharmacol. 2008;28:114–6.CrossRefPubMedGoogle Scholar
  97. 97.
    Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008;64:527–32.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Sheline YI, Price JL, Yan Z, Mintun MA. Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proc Natl Acad Sci U S A. 2010;107:11020–5.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Shiroma PR, Albott CS, Johns B, Thuras P, Wels J, Lim KO. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17:1–9.CrossRefGoogle Scholar
  100. 100.
    Sos P, Kilrova M, Novak T, Kohutova B, Horacek J, Palenicek T. Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett. 2013;34:287–93.PubMedGoogle Scholar
  101. 101.
    Stahl SM. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiatry. 2008;69:1673–4.CrossRefPubMedGoogle Scholar
  102. 102.
    Stern RG, Schmeidler J, Davidson M. Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry. 1997;42:138–43.CrossRefPubMedGoogle Scholar
  103. 103.
    Tang WK, Morgan CJ, Lau GC, Liang HJ, Tang A, Ungvari GS. Psychiatric morbidity in ketamine users attending counseling and youth outreach services. Subst Abus. 2015;36:67–74.Google Scholar
  104. 104.
    Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, Vanmeter S, Harriett AE, Wang Y. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005;66:974–81.CrossRefPubMedGoogle Scholar
  105. 105.
    Tracy DK, de Sousa de Abreu M, Nalesnik N, Mao L, Lage C, Shergill S. Neuroimaging effects of 1Hz right temporoparietal rTMS on normal auditory processing: implications for clinical hallucination treatment paradigms. J Clin Neurophysiol. 2014;31:541–6.Google Scholar
  106. 106.
    Tracy DK, O’Daly O, Joyce DW, Michalopoulou PG, Basit BB, Dhillon G, Mcloughlin DM, Shergill SS. An evoked auditory response fMRI study of the effects of rTMS on putative AVH pathways in healthy volunteers. Neuropsychologia. 2010;48:270–7.CrossRefPubMedGoogle Scholar
  107. 107.
    Tracy DK, Shergill SS. Mechanisms underlying auditory hallucinations-understanding perception without stimulus. Brain Sci. 2013;3:642–69.CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    Traynelis SF. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62:405–96.CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Uosukainen H, Tacke U, Winstock AR. Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users. Int J Drug Policy. 2015;26:78–83.Google Scholar
  110. 110.
    Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 2011;191:122–7.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res. 2000;34:35–43.CrossRefPubMedGoogle Scholar
  112. 112.
    Wang X, Chen Y, Zhou X, Liu F, Zhang T, Zhang C. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J ECT. 2012;28:128–32.CrossRefPubMedGoogle Scholar
  113. 113.
    WHO. The global burden of disease: 2004 update. Geneva: World Health Organisation; 2008.Google Scholar
  114. 114.
    Wong SW, Lee KF, Wong J, Ng WW, Cheung YS, Lai PB. Dilated common bile ducts mimicking choledochal cysts in ketamine abusers. Hong Kong Med J. 2009;15:53–6.PubMedGoogle Scholar
  115. 115.
    Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009;54:1847–56.CrossRefPubMedGoogle Scholar
  116. 116.
    Yamada N, Katsuura G, Ochi Y, Ebihara K, Kusakabe T, Hosoda K, Nakao K. Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology. 2011;152:2634–43.CrossRefPubMedGoogle Scholar
  117. 117.
    Yang C, Hu YM, Zhou ZQ, Zhang GF, Yang JJ. Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test. Ups J Med Sci. 2013;118:3–8.CrossRefPubMedPubMedCentralGoogle Scholar
  118. 118.
    Yoosefi A, Sepehri AS, Kargar M, Akhondzadeh S, Sadeghi M, Rafei A, Alimadadi A, Ghaeli P. Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study. J ECT. 2014;30:15–21.CrossRefPubMedGoogle Scholar
  119. 119.
    Zarate Jr CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939–46.CrossRefPubMedPubMedCentralGoogle Scholar
  120. 120.
    Zarate Jr CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–64.CrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  • Derek K. Tracy
    • 1
    • 2
  • Caroline Caddy
    • 2
  • Sukhwinder S. Shergill
    • 3
    • 2
  1. 1.Oxleas NHS Foundation TrustLondonUK
  2. 2.Cognition Schizophrenia and Imaging Laboratory, Department of Psychosis Studies, the Institute of PsychiatryKing’s College LondonLondonUK
  3. 3.South London and Maudsley, NHS Foundation TrustLondonUK

Personalised recommendations